Research By Markets adds Market Research Report - Thalassemia – Pipeline Review, H2 2019
For detailed information: https://www.researchbymarkets.com/report/thalassemia-pipeline-review-h2-2019-451044.html
Thalassemia – Pipeline Review, H2 2019
Thalassemia – Pipeline Review, H2 2019, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body’s ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Thalassemia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 12, 7, 1, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.
Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
– The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acceleron Pharma Inc
Agios Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Aruvant Sciences Inc
ASC Therapeutics Inc
Beam Therapeutics Inc
bluebird bio Inc
Cell Source Inc
CRISPR Therapeutics AG
Editas Medicine Inc
Errant Gene Therapeutics LLC
Fulcrum Therapeutics Inc
Gamida Cell Ltd
Gilead Sciences Inc
Ionis Pharmaceuticals Inc
IRBM Science Park SpA
La Jolla Pharmaceutical Company
Merck & Co Inc
Merganser Biotech Inc
Orchard Therapeutics Plc
Phoenicia Biosciences Inc
Protagonist Therapeutics Inc
Rare Partners Srl
Regenacy Pharmaceuticals LLC
Sangamo Therapeutics Inc
Sanquin Plasma Products BV
Silence Therapeutics Plc
Trucode Gene Repair Inc
Vifor Pharma AG
For queries regarding this report: https://www.researchbymarkets.com/sample-request/451044